We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KOG:EURONEXT OSLOKongsberg Gruppen ASA Analysis

Data as of 2026-05-28 - not real-time

¥3,215.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Nihon Dempa Kogyo (KOG) is trading well above its 20‑day (¥2,322), 50‑day (¥1,806) and 200‑day (¥1,217) moving averages at ¥3,215, confirming a strong bullish price momentum. The 14‑day RSI of 72 signals that the stock is in overbought territory, while a bullish MACD histogram (+¥80) suggests the upward trend still has technical support. However, the discounted cash‑flow fair value of ¥1,810 and analyst target of ¥1,340 imply a substantial downside of roughly 58%, and the Fear & Greed Index at 91.5 reflects “Extreme Greed” in the market. Fundamentals show solid top‑line growth (+10% YoY revenue) and an improving net profit (¥2.07 bn vs ¥1.79 bn), yet margins remain thin (operating margin 7.9%, profit margin 3.8%) and free cash flow is negative, while debt‑to‑equity sits at a high 92.5%. The dividend yield of 1.06% with a 33% payout ratio appears modest but may be strained by the cash‑flow shortfall. Volatility is elevated at 114% over the past 30 days and beta is near market (0.88), indicating higher price swings. In this context, the stock’s current valuation is stretched, making short‑term downside risk prominent despite the bullish technical backdrop.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • price far above DCF and analyst targets
  • overbought RSI and high volatility
  • negative free cash flow and high leverage

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • steady revenue growth and improving earnings
  • forward PE compression to 18.5 suggesting valuation correction
  • ongoing technical bullishness but elevated risk

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • industry positioning in high‑growth electronic components
  • potential for margin improvement and cash‑flow turnaround
  • valuation gap offering upside if price reverts toward fair value

Key Metrics & Analysis

Financial Health

Revenue Growth10.20%
Profit Margin3.78%
P/E Ratio35.8
ROE6.76%
ROA2.84%
Debt/Equity92.54
P/B Ratio2.4
Op. Cash Flow¥4.2B
Free Cash Flow¥-4768000000
Industry P/E40.4

Technical Analysis

TrendBullish
RSI72.2
Support¥1,720.00
Resistance¥3,650.00
MA 20¥2,322.65
MA 50¥1,805.80
MA 200¥1,217.03
MACDBullish
VolumeIncreasing
Fear & Greed Index91.54

Valuation

Fair Value¥1,810.49
Target Price¥1,340.00
Upside/Downside-58.32%
GradeOvervalued
TypeGrowth
Dividend Yield1.06%

Risk Assessment

Beta0.88
Volatility114.05%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.